“The new Industrial Development and Innovation Department is consistent with the vision we have of our industrial activities in the future”, said Philippe Luscan, SVP, Industrial Affairs, Sanofi-Aventis.
“Our main objective is to get even more involved in the dynamic of our
products’ Life Cycle Management thanks to innovations, such as new processes, new technologies or new medical devices”, he added.
In the short and medium term, the Group’s performance will be improved in particular by strengthening our industrial organization through the development of new drug delivery systems and medical devices adapted to patients’ needs, as well as a better understanding of the regions’ expectations.
Jean-Philippe holds a Master of Sciences and a post-graduate degree in statistics applied to medicine. He started his career at Servier, in 1984. He joined Synthelabo in 1990 as cardiovascular development director, then Sanofi-Synthelabo Research as vice president International Clinical Operations. After the merger with Aventis, he was appointed vice president International Clinical Development.
